CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent

2016-10-01

Annals of Oncology , Volume 27 p. vi262

Additional Metadata
Persistent URL	doi.org/10.1093/annonc/mdw372.50, hdl.handle.net/1765/126448
Journal	Annals of Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Wit, R., Fizazi, K., Efstathiou, E., Dittamore, R. (R.), Hitier, S. (S.), Pantel, K., … de Bono, J. (2016). CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent. Annals of Oncology, 27. doi:10.1093/annonc/mdw372.50

Publication